(https://www.marketwatch.com/story/eli-lilly-is-suing-pharmacies-and-peptide-vendors-over-sales-of-the-next-big-weight-loss-drug-retatrutide-22434cce?mod=mw_rss_topstories) reads like a pricing-power crisis dressed up as IP enforcement. When a $500B pharma giant has to sue mom-and-pop compounders to protect margins, the game's over—consumers are voting with their feet for the cheaper alternative.

Research these companies